Netanyahu says cancer removed, first public disclosure after prostate surgery

Benjamin Netanyahu disclosed that doctors had removed a malignant prostate tumour, his first public acknowledgment of cancer, as Israel’s longest-serving leader faced renewed questions about health, continuity and disclosure while the country remained under military and political strain.

His office published the annual medical report on Friday, April 24, 2026, though the document was dated April 20. It said doctors found a very early-stage malignant prostate tumour during routine follow-up after a prostate operation on December 29, 2024, at Hadassah Ein Kerem Hospital in Jerusalem. That surgery had originally been described as treatment for benign enlargement of the prostate and was reported as successful and without complications.

The report said a later MRI revealed a minuscule suspicious lesion, with some coverage describing it as smaller than 1 millimeter. Further tests confirmed early-stage prostate cancer, with no evidence of spread or metastasis. Netanyahu said he was in “excellent physical condition” after receiving targeted treatment, and he said he chose treatment rather than simply monitoring the tumour.

Netanyahu also said he had asked for the report to be delayed by about two months so it would not be released at the height of the war and used by Iran for propaganda. The timing underscored how even a medical update can be pulled into the regional information struggle, especially for a prime minister overseeing war planning, security decisions and fragile coalition politics.

The disclosure sharpened attention on the standards democracies apply when leaders face serious medical issues. Netanyahu had already undergone pacemaker implantation in July 2023, and his health had been watched closely after the prostate procedure in late 2024 and an earlier urinary tract infection. In February 2026, his office had denied rumors that he had prostate cancer, making Friday’s announcement a striking reversal in public messaging.

For Israelis, the issue is not only the diagnosis itself, but the degree of transparency around the person making life-or-death decisions during war. A leader can remain in office after medical treatment, but the public still needs enough information to judge decision-making capacity, succession planning and whether institutions are prepared if a sudden change becomes necessary. In a system already under intense pressure, the line between private illness and public accountability is unusually thin, and Netanyahu’s disclosure now sets a new benchmark for how much a wartime government says about the health of its chief decision-maker.